Filter by Event: ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Lefamulin Dose Justification and Susceptibility Breakpoint Determinations for Patients With Community-Acquired Bacterial Pneumonia
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Lefamulin Dose Justification and Susceptibility Breakpoint Determinations for Patients With Community-Acquired Bacterial Pneumonia. Lead author: SM Bhavnani, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster #19
Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program
Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program. Lead author: S Paukner, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # T-74
Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018
Ceftobiprole Activity against Pathogens Causing Bacterial Skin and Skin Structure Infections in the United States from 2016 through 2018. Lead author: LR Duncan, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster# T-67
Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018
Cefepime-Zidebactam (WCK 5222) Activity against Clinical Isolates of Non-Fermentative Gram-Negative Bacilli Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 69
Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018
Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster 70
In vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecluarly Characterized β-Lactamase Genes
In vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecluarly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster #73
In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program
In Vitro Activity of KHP-3757 and Comparators against Recent and Molecularly Characterized Pseudomonas aeruginosa Isolates from a Global Surveillance Program. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster
Omadacycline Is Not a Substrate for Clinically Relevant β-Lactamase Enzymes
Omadacycline Is Not a Substrate for Clinically Relevant β-Lactamase Enzymes. Lead author: RE Mendes, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-62
Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates
Activity of KBP-7072 against Recent and Molecularly Characterized Acinetobacter baumannii Isolates. Lead author: MD Huband, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # W-69
